Clinical efficacy and safety of first-line treatments in patients with mantle cell lymphoma: A systematic literature review.

in Critical reviews in oncology/hematology by Neerav Monga, Constantine Tam, Jamie Garside, Matthew S Davids, Katherine Ward, Joan Quigley, Lori Parisi, Christoph Tapprich

TLDR

  • The study examined the efficacy and safety of first-line therapies for MCL, a rare NHL subtype with short survival.
  • Patient outcomes varied based on patient age and suitability for ASCT, with elderly patients ineligible for transplant having poorer outcomes.
  • The study highlights the need for newer treatments that improve patient outcomes for MCL patients, particularly elderly patients who are ineligible for transplant.

Abstract

Mantle cell lymphoma (MCL) is a rare form of non-Hodgkin's lymphoma (NHL) with a median overall survival (OS) of approximately 3-5 years. Systematic literature reviews (SLRs) identified efficacy and safety data for first-line therapies, reported in randomised controlled trials (RCTs) and non-randomised interventional studies (NRISs). Nine and 20 independent studies were included in the RCT and NRISs SLRs, respectively. Differences in the regimens and patient outcomes varied according to patient age and suitability for autologous stem cell transplantation (ASCT). In elderly patients ineligible for transplant, OS ranged from 40 months to 69.6 months. In young transplant-eligible patients, OS ranged from 53 months to 152.4 months. Despite the paucity of directly comparable evidence on the efficacy and safety of MCL therapies, these SLRs highlight that MCL remains a difficult NHL subtype to treat, with short survival highlighting the unmet need for newer treatments that improve patient outcomes.

Overview

  • The study examined the efficacy and safety data of first-line therapies for mantle cell lymphoma (MCL), a rare form of non-Hodgkin's lymphoma (NHL).
  • The study included systematic literature reviews (SLRs) of randomized controlled trials (RCTs) and non-randomized interventional studies (NRISs) to identify differences in patient outcomes based on patient age and suitability for autologous stem cell transplantation (ASCT).
  • The primary objective of the study was to identify effective and safe therapies for MCL patients, highlighting the need for newer treatments that improve patient outcomes.

Comparative Analysis & Findings

  • The study found that patient outcomes varied according to patient age and suitability for ASCT, with elderly patients ineligible for transplant having a median overall survival (OS) ranging from 40 months to 69.6 months.
  • In contrast, young transplant-eligible patients had a median OS ranging from 53 months to 152.4 months.
  • The study identified a paucity of directly comparable evidence on the efficacy and safety of MCL therapies, highlighting the need for more research in this area.

Implications and Future Directions

  • The study highlights the unmet need for newer treatments that improve patient outcomes for MCL patients, particularly elderly patients who are ineligible for transplant.
  • Future research should focus on identifying effective and safe therapies for MCL, including the evaluation of novel treatments and clinical trials.
  • The study underscores the importance of considering patient age and suitability for ASCT when selecting therapies for MCL patients.
Read Full Article